Related by context. Frequent words. (Click for all words.) 59 Therein lurks 58 Secondary endpoints include 58 Secondary endpoints included 55 Hill Rom enhancing 55 efficacy tolerability 55 TranSwitch indebtedness 55 tolerability profiles 54 approvability 54 Entereg R 53 MAA submission 53 oxymorphone ER 53 APPRAISE 53 R sorafenib tablets 53 vosaroxin 53 ATACAND 52 Visit www.otc advisors.com 52 Egrifta 52 By HARVEY SIMPSON 52 Visit www.fda.gov medwatch 52 interferon gamma 1b 52 triple VEGF receptor 52 ValuEngine Rating 52 Genz # 52 Entereg TM 51 % #F# 4v.jsn 51 dlazarus@sfchronicle.com 51 By Laurie Kulikowski 51 YOUR LOCAL ANIMAL SHELTER 51 paliperidone ER 51 Phenoptin 51 Panzem R 51 AVANDIA 51 By Laurelle Gilbert 51 motesanib 51 ARCOXIA 51 postmarketing surveillance 51 Biologic License Application BLA 51 forodesine 51 SILENOR ™ 50 orBec ® oral beclomethasone 50 us info@tuvps.co.uk 50 thetreatment 50 Please respond insightfully 50 By Amy Boerema 50 hormone receptor negative 50 Plenaxis R 50 By Majuto Omary 50 receiving VELCADE 50 TOLAMBA 50 Sodium oxybate 50 faropenem 50 TOCOSOL Paclitaxel 49 HMG CoA reductase inhibitors 49 cardiovascular disease hypertension 49 XL# XL# XL# XL# 49 SYMMETRY trial 49 severe hypersensitivity reactions 49 Pat El Hinnawy 49 SUCCEED trial 49 please visit http:/www.biogenidec.com 49 pharmacodynamic effects 49 amrubicin 49 should consult NeurogesX 49 BiovaxID TM 49 FACTIVE R gemifloxacin 49 By Priyanka Dayal 49 INVEGA ® 49 hospitals physicians homecare 49 Reader Comment Guidelines 49 By CINDY PETERSON 49 Somaxon ability 49 Understanding Universal BCAR 49 spokesman Tony Plohoros 49 CMV vaccine 49 triglyceride lowering 49 Toasty Peanut Butter 49 PREOS 49 By DAVID SCHEPP 49 signal detection CTSD 49 tumor lysis syndrome 49 mortality morbidity 49 SILENOR TM 49 HBO MTV VH1 49 4 chars 49 Nabi HB 48 cirrhosis liver failure 48 Certican 48 orBec 48 Fibrillex TM 48 Omigard 48 refractory chronic lymphocytic 48 Nortel strategic alliances 48 By JENNIFER RADCLIFFE 48 Secondary endpoints 48 By Tom Polansek 48 LibiGel Phase III 48 prognostic indicators 48 BioSante licensees 48 pafuramidine 48 2 methoxyestradiol 48 QTinno